413 related articles for article (PubMed ID: 24931142)
21. Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma.
Chen Y; Zhang L; Yang C; Han J; Wang C; Zheng C; Zhou Y; Lv J; Song Y; Zhu J
Bioorg Med Chem; 2016 Mar; 24(5):957-66. PubMed ID: 26819001
[TBL] [Abstract][Full Text] [Related]
22. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
[TBL] [Abstract][Full Text] [Related]
23. Long noncoding RNA HAGLROS promotes cell proliferation, inhibits apoptosis and enhances autophagy via regulating miR-5095/ATG12 axis in hepatocellular carcinoma cells.
Wei H; Hu J; Pu J; Tang Q; Li W; Ma R; Xu Z; Tan C; Yao T; Wu X; Long X; Wang J
Int Immunopharmacol; 2019 Aug; 73():72-80. PubMed ID: 31082725
[TBL] [Abstract][Full Text] [Related]
24. The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism.
Tian LY; Smit DJ; Jücker M
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768977
[TBL] [Abstract][Full Text] [Related]
25. VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway.
Pu Z; Duda DG; Zhu Y; Pei S; Wang X; Huang Y; Yi P; Huang Z; Peng F; Hu X; Fan X
J Transl Med; 2022 May; 20(1):212. PubMed ID: 35562734
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of microRNA-133b is associated with the increased survival of patients with hepatocellular carcinoma after curative hepatectomy: Involvement of the EGFR/PI3K/Akt/mTOR signaling pathway.
Wang X; Zeng J; Wang L; Zhang X; Liu Z; Zhang H; Dong J
Oncol Rep; 2017 Jul; 38(1):141-150. PubMed ID: 28586051
[TBL] [Abstract][Full Text] [Related]
27. Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types.
Schwaederle M; Elkin SK; Tomson BN; Carter JL; Kurzrock R
Cell Cycle; 2015; 14(14):2355-61. PubMed ID: 26030731
[TBL] [Abstract][Full Text] [Related]
28. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
Kim MN; Lee SM; Kim JS; Hwang SG
Cancer Chemother Pharmacol; 2019 Oct; 84(4):809-817. PubMed ID: 31385002
[TBL] [Abstract][Full Text] [Related]
29. EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma.
Pellegrino R; Calvisi DF; Neumann O; Kolluru V; Wesely J; Chen X; Wang C; Wuestefeld T; Ladu S; Elgohary N; Bermejo JL; Radlwimmer B; Zörnig M; Zender L; Dombrowski F; Evert M; Schirmacher P; Longerich T
Hepatology; 2014 May; 59(5):1886-99. PubMed ID: 24285179
[TBL] [Abstract][Full Text] [Related]
30. Itraconazole exerts anti-liver cancer potential through the Wnt, PI3K/AKT/mTOR, and ROS pathways.
Wang W; Dong X; Liu Y; Ni B; Sai N; You L; Sun M; Yao Y; Qu C; Yin X; Ni J
Biomed Pharmacother; 2020 Nov; 131():110661. PubMed ID: 32942154
[TBL] [Abstract][Full Text] [Related]
31. TANGO1 interacts with NRTN to promote hepatocellular carcinoma progression by regulating the PI3K/AKT/mTOR signaling pathway.
Man J; Zhou W; Zuo S; Zhao X; Wang Q; Ma H; Li HY
Biochem Pharmacol; 2023 Jul; 213():115615. PubMed ID: 37211171
[TBL] [Abstract][Full Text] [Related]
32. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.
Chen H; Wong CC; Liu D; Go MYY; Wu B; Peng S; Kuang M; Wong N; Yu J
Theranostics; 2019; 9(18):5246-5260. PubMed ID: 31410213
[No Abstract] [Full Text] [Related]
33. Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway.
Wang H; Zhang C; Xu L; Zang K; Ning Z; Jiang F; Chi H; Zhu X; Meng Z
Oncotarget; 2016 Apr; 7(15):20193-208. PubMed ID: 26958938
[TBL] [Abstract][Full Text] [Related]
34. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
Araki K; Miyoshi Y
Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
[TBL] [Abstract][Full Text] [Related]
35. New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors.
Golob-Schwarzl N; Krassnig S; Toeglhofer AM; Park YN; Gogg-Kamerer M; Vierlinger K; Schröder F; Rhee H; Schicho R; Fickert P; Haybaeck J
Eur J Cancer; 2017 Sep; 83():56-70. PubMed ID: 28715695
[TBL] [Abstract][Full Text] [Related]
36. Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.
Pierobon M; Ramos C; Wong S; Hodge KA; Aldrich J; Byron S; Anthony SP; Robert NJ; Northfelt DW; Jahanzeb M; Vocila L; Wulfkuhle J; Gambara G; Gallagher RI; Dunetz B; Hoke N; Dong T; Craig DW; Cristofanilli M; Leyland-Jones B; Liotta LA; O'Shaughnessy JA; Carpten JD; Petricoin EF
Clin Cancer Res; 2017 Aug; 23(16):4919-4928. PubMed ID: 28446508
[No Abstract] [Full Text] [Related]
37. SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway.
Hong SW; Jung KH; Lee HS; Choi MJ; Son MK; Zheng HM; Hong SS
Cancer Sci; 2012 Nov; 103(11):1929-37. PubMed ID: 22909393
[TBL] [Abstract][Full Text] [Related]
38. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway.
Zhang Z; Zhu J; Huang Y; Li W; Cheng H
Diagn Pathol; 2018 Nov; 13(1):85. PubMed ID: 30390677
[TBL] [Abstract][Full Text] [Related]
39. Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors.
Bellmunt J; Werner L; Leow JJ; Mullane SA; Fay AP; Riester M; Van Hummelen P; Taplin ME; Choueiri TK; Van Allen E; Rosenberg J
PLoS One; 2015; 10(6):e0124711. PubMed ID: 26039708
[TBL] [Abstract][Full Text] [Related]
40. Targeted inhibition of ACK1 can inhibit the proliferation of hepatocellular carcinoma cells through the PTEN/AKT/mTOR pathway.
Wang B; Song K; Chen L; Su H; Gao L; Liu J; Huang A
Cell Biochem Funct; 2020 Jul; 38(5):642-650. PubMed ID: 32162707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]